Nicole E Caporino1, Dara Sakolsky2, Douglas M Brodman3, Joseph F McGuire4, John Piacentini4, Tara S Peris4, Golda S Ginsburg5, John T Walkup6, Satish Iyengar7, Philip C Kendall8, Boris Birmaher2. 1. American University, Washington, DC. Electronic address: caporino@american.edu. 2. University of Pittsburgh School of Medicine, Pittsburgh, PA. 3. New York University Langone Medical Center, New York. 4. University of California-Los Angeles School of Medicine, Los Angeles. 5. University of Connecticut Health Center, Farmington. 6. New York-Presbyterian Weill Cornell Medical Center, New York. 7. University of Pittsburgh. 8. Temple University, Philadelphia.
Abstract
OBJECTIVE: To determine optimal percent reduction and raw score cutoffs on the parent- and child-report Screen for Child Anxiety Related Emotional Disorders (SCARED) for predicting treatment response and remission among youth with anxiety disorders. METHOD:Data were obtained from youth (N = 438; 7-17 years old) who completed treatment in the Child/Adolescent Anxiety Multimodal treatment Study, a multisite, randomized clinical trial that examined the relative efficacy of medication (sertraline), cognitive-behavioral therapy (Coping Cat), their combination, and pill placebo for the treatment of separation anxiety disorder, generalized anxiety disorder, and social phobia. The parent- and youth-report SCARED were administered at pre- and posttreatment. Quality receiver operating characteristic methods evaluated the performance of various SCARED percent reduction and absolute cutoff scores in predicting treatment response and remission, as defined by posttreatment ratings on the Clinical Global Impression scales and the Anxiety Disorders Interview Schedule. RESULTS: Reductions of 55% on the SCARED-Parent and 50% on the SCARED-Youth optimally predicted treatment response. Posttreatment absolute raw scores of 10 (SCARED-Parent) and 12 (SCARED-Youth) optimally predicted remission in the total sample, although separate SCARED-Parent cutoffs for children (12-13) and adolescents (9) showed greatest quality of efficiency. Each cutoff significantly predicted response and remission at 6-month follow-up. CONCLUSION: Results serve as guidelines for operationalizing treatment response and remission on the SCARED, which could help clinicians systematically monitor treatment outcomes of youth with anxiety disorders in a cost- and time-efficient manner. Clinical trial registration information-Child and Adolescent Anxiety Disorders (CAMS); http://clinicaltrials.gov/; NCT00052078.
RCT Entities:
OBJECTIVE: To determine optimal percent reduction and raw score cutoffs on the parent- and child-report Screen for ChildAnxiety Related Emotional Disorders (SCARED) for predicting treatment response and remission among youth with anxiety disorders. METHOD: Data were obtained from youth (N = 438; 7-17 years old) who completed treatment in the Child/Adolescent Anxiety Multimodal treatment Study, a multisite, randomized clinical trial that examined the relative efficacy of medication (sertraline), cognitive-behavioral therapy (Coping Cat), their combination, and pill placebo for the treatment of separation anxiety disorder, generalized anxiety disorder, and social phobia. The parent- and youth-report SCARED were administered at pre- and posttreatment. Quality receiver operating characteristic methods evaluated the performance of various SCARED percent reduction and absolute cutoff scores in predicting treatment response and remission, as defined by posttreatment ratings on the Clinical Global Impression scales and the Anxiety Disorders Interview Schedule. RESULTS: Reductions of 55% on the SCARED-Parent and 50% on the SCARED-Youth optimally predicted treatment response. Posttreatment absolute raw scores of 10 (SCARED-Parent) and 12 (SCARED-Youth) optimally predicted remission in the total sample, although separate SCARED-Parent cutoffs for children (12-13) and adolescents (9) showed greatest quality of efficiency. Each cutoff significantly predicted response and remission at 6-month follow-up. CONCLUSION: Results serve as guidelines for operationalizing treatment response and remission on the SCARED, which could help clinicians systematically monitor treatment outcomes of youth with anxiety disorders in a cost- and time-efficient manner. Clinical trial registration information-Child and Adolescent Anxiety Disorders (CAMS); http://clinicaltrials.gov/; NCT00052078.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Corinne Hannan; Michael J Lambert; Cory Harmon; Stevan Lars Nielsen; David W Smart; Kenichi Shimokawa; Scott W Sutton Journal: J Clin Psychol Date: 2005-02
Authors: Philip C Kendall; Scott N Compton; John T Walkup; Boris Birmaher; Anne Marie Albano; Joel Sherrill; Golda Ginsburg; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; Lindsey Bergman; Dara Sakolsky; Cindy Suveg; Satish Iyengar; John March; John Piacentini Journal: J Anxiety Disord Date: 2010-02-06
Authors: William W Hale; Elisabetta Crocetti; Quinten A W Raaijmakers; Wim H J Meeus Journal: J Child Psychol Psychiatry Date: 2011-01 Impact factor: 8.982
Authors: Nicole E Caporino; Douglas M Brodman; Philip C Kendall; Anne Marie Albano; Joel Sherrill; John Piacentini; Dara Sakolsky; Boris Birmaher; Scott N Compton; Golda Ginsburg; Moira Rynn; James McCracken; Elizabeth Gosch; Courtney Keeton; John March; John T Walkup Journal: J Am Acad Child Adolesc Psychiatry Date: 2012-11-30 Impact factor: 8.829
Authors: Joseph F McGuire; Nicole E Caporino; Sophie A Palitz; Philip C Kendall; Anne Marie Albano; Golda S Ginsburg; Boris Birmaher; John T Walkup; John Piacentini Journal: Depress Anxiety Date: 2019-06-24 Impact factor: 6.505
Authors: Sophie A Palitz; Nicole E Caporino; Joseph F McGuire; John Piacentini; Anne Marie Albano; Boris Birmaher; John T Walkup; Scott N Compton; Golda S Ginsburg; Philip C Kendall Journal: J Am Acad Child Adolesc Psychiatry Date: 2018-04-17 Impact factor: 8.829
Authors: Caroline W Oppenheimer; Jennifer S Silk; Kyung Hwa Lee; Ronald E Dahl; Erika Forbes; Neal Ryan; Cecile D Ladouceur Journal: Child Psychiatry Hum Dev Date: 2020-04
Authors: Joseph F McGuire; Daniel A Geller; Tanya K Murphy; Brent J Small; Arianna Unger; Sabine Wilhelm; Eric A Storch Journal: Behav Ther Date: 2018-06-22
Authors: Natoshia R Cunningham; Anjana Jagpal; Sarah Nelson; Kristen E Jastrowski Mano; Susan T Tran; Anne M Lynch-Jordan; Keri Hainsworth; James Peugh; Constance A Mara; Susmita Kashikar-Zuck Journal: Clin J Pain Date: 2019-03 Impact factor: 3.442